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Abstract
Introduction: Patients with HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) become progressively
impaired, with chronic pain, immobility and bladder, bowel and sexual dysfunction. Tested antiretroviral therapies have not
been effective and most patients are offered a short course of corticosteroids or interferon-a, physiotherapy and
symptomatic management. Pathogenesis studies implicate activated T-lymphocytes and cytokines in tissue damage. We
therefore tested the hypothesis that inhibition of T-cell activation with ciclosporin A would be safe and clinically beneficial
in patients with early and/or clinically progressing HAM/TSP.
Materials and Methods: Open label, proof of concept, pilot study of 48 weeks therapy with the calcineurin antagonist,
ciclosporin A (CsA), in seven patients with ‘early’ (,two years) or ‘progressive’ (.50% deterioration in timed walk during the
preceding three months) HAM/TSP. Primary outcomes were incidence of clinical failure at 48 weeks and time to clinical
failure.
Results: All patients completed 72 weeks study participation and five showed objective evidence of clinical improvement
after 3 months treatment with CsA. Two patients exhibited clinical failure over 6.4 person-years of follow-up to week 48.
One patient had a .2 point deterioration in IPEC (Insituto de Pesquisa Clinica Evandro Chagas) disability score at weeks 8
and 12, and then stopped treatment. The other stopped treatment at week 4 because of headache and tremor and
deterioration in timed walk, which occurred at week 45. Overall pain, mobility, spasticity and bladder function improved by
48 weeks. Two patients recommenced CsA during follow-up due to relapse.
Conclusions: These data provide initial evidence that treatment with CsA is safe and may partially reverse the clinical
deterioration seen in patients with early/progressive HAM/TSP. This trial supports further investigation of this agent’s safety
and effectiveness in larger, randomised controlled studies in carefully selected patients with disease progression.
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Introduction
An estimated 20 million people are infected with HTLV-1
worldwide [1] of which approximately 8% (,2 million) will
develop HTLV-1-associated diseases, most notably adult T-cell
leukaemia/lymphoma (ATLL) [2], HTLV-1-associated myelopa-
thy/tropical spastic paraparesis (HAM/TSP) [3], HTLV-1-asso-
ciated uveitis (HAU) [4] and infective dermatitis [5].
An association between myelopathy and HTLV-1 seropositivity
in serum and cerebrospinal fluid (CSF) was first reported in 1985,
in patients with Tropical Spastic Paraparesis (TSP) in Martinique
[3], and independently in Japan in 1986, where the condition was
termed HTLV-1-associated myelopathy (HAM) [6]. It is accepted
that HAM/TSP, a chronic and progressive spastic paraparesis in
patients living in both endemic and non-endemic countries [7,8,9],
is an inflammatory condition [10].
But almost thirty years after its discovery little is known
about how best to treat HAM/TSP [11]. Although corticoste-
roids [12,13] and interferon-a/b [14] have been used as
therapy for HAM/TSP, they are only of transient benefit
(weeks), cause serious side-effects and have not been compared
to placebo.
Particular challenges to designing clinical trials in HAM/TSP
include the uncertainties relating to the following questions:
i) Does the stage of disease influence treatment outcome?
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ii) Which treatment approach should be adopted – antiviral or
anti-inflammatory?
iii) How long should treatment be given?
In 2006 a revision of the original WHO diagnostic criteria of
HAM/TSP allowed ascertainment of three diagnostic levels:
definite, probable and possible after excluding all conditions that
could mimic HAM/TSP [15]. To monitor clinical progression of
HAM/TSP and therapy response, clinicians now differentiate
between i) early and late ii) clinically progressive and non-
progressive and iii) active and inactive definite HAM/TSP [11,16]
(and personal communication with the HAM/TSP clinical trial
subgroup). Immunosuppressive therapy is especially attractive in
patients with early, clinically progressive, or active HAM/TSP,
which are defined as onset of symptoms #2 years, evidence of
clinical progression, such as deterioration of timed walk or
progression in disability scales, or evidence of CNS inflammatory
activity from cerebrospinal fluid (CSF) analysis retrospectively.
However immunosuppressive therapy given to patients with
HTLV-1 infection may increase the chance of developing ATLL.
Cases of ATLL following organ transplantation, for which much
greater immunosuppression is prescribed than in this study, have
been reported but the risk has not been quantified for any specific
immunosuppressive treatment [17,18,19,20,21,22].
Also the optimal duration of any therapy for patients with
HAM/TSP has never been examined and due to its side-effects
long-term administration of corticosteroids, the most commonly
prescribed first line treatment, is not recommended.
With the aim to identify a long-term, safe corticosteroid-sparing
immunosuppressive therapy for patients with HAM/TSP, we
conducted an open, proof of principle study, which examined the
potential clinical and immunological efficacy and the safety of
Ciclosporin A (CsA) in patients with early, progressive HAM/TSP
(September 2006 to January 2010, NCT00773292).
CsA is used routinely and long-term in post-allergenic organ
transplants as well as inflammatory dermatological and musculo-
skeletal disease such as psoriasis, ectopic dermatitis and rheuma-
toid arthritis. It has also been used for idiopathic uveitis and severe
cases of immune-mediated haemolytic anaemia.
The primary objective of this study was to determine whether
CsA treatment for 48 weeks improved clinical outcome measures
of patients with early or progressing definite HAM/TSP. The
secondary objectives were to determine i) the safety of CsA, ii) the
effects of CsA on HTLV-1 proviral load in blood and CSF and iii)
the effect of CsA on markers of T-cell activation and proliferation.
The study also explored the mechanism of pathogenesis of HAM/
TSP by analysing the effect of CsA on the severity and progression
of HAM/TSP.
Materials and Methods
Study design
The study protocol, patient information sheet and consent form
were submitted to the National Research Ethics Service and
approved by the Oxfordshire ‘A’ Research Ethics Committee
(Reference 06/Q1604/75); Clinical Trial Registration: Clinical-
trials.gov: NCT00773292. Eligible patients had definite HAM/
TSP, as defined by ‘Belem criteria’ [15] and either had developed
first symptoms within the last two years or had progressive disease,
as defined by $50% documented deterioration in 10 m timed
walk over the preceding three months. All patients were older than
16 years, not pregnant or breastfeeding, and were serologically
negative when tested for HIV 1/2, HBV, HCV, syphilis and
Strongyloides stercoralis. There was no evidence of pulmonary
tuberculosis on chest x-rays and none of the patients had a history
of malignant or autoimmune disease. After giving written
informed consent, patients attending the National Centre for
Human Retrovirology at St Mary’s Hospital, London, underwent
two baseline visits at least one day and no more than four weeks
apart and trial therapy was commenced after the 2nd baseline visit.
Patients were recruited sequentially and initially treated with oral
CsA 2.5–5 mg/kg/day divided into two, 12-hourly doses and
subsequently dose-adjusted to maintain plasma trough levels
between 80–100ng/ml for 48 weeks with CsA plasma concentra-
tions monitored at each on-treatment study visit. Post-treatment
patients were followed for an additional 24 weeks.
The primary outcome measures were i) incidence of clinical
failure at 48 weeks and ii) time to clinical failure. Clinical failure was
defined as any of the following i) lack of any objective improvement
after three months of therapy, ii) greater than two point
deterioration (increase) in the IPEC 1 scale compared with baseline
at two consecutive visits excluding weeks 2 and 4 and iii) $30%
deterioration in timed walk compared with baseline at any time
during the trial. Objective improvement was defined as any of the
following comparing baseline measurements to 12, 24 and 48 weeks:
i) one point decrease in the IPEC 1 scale (Instituto de Pesquisa
Clı´nica Evandro Chagas), ii) .30% improvement in 10 m timed
walk, iii) visual analogue pain score reduced by .2 points, iv)
reduction of frequency or nocturia by greater than one or reduction
of residual volume by more than 10% at two consecutive visits.
Secondary outcomes were the following clinical and laboratory
variables measured at 12, 24, 48 and 72 weeks: Seconds needed to
walk 10 meters (sec/10 m TW), change in walking aid, maximum
pain (visual analogue score 0–10/10 cm VAS), modified Ashworth
scale score (MASS, Appendix S1), walking scale (MSWS-12,
Appendix S2), IPEC 1 and 2 disability scale score (Appendix S3),
bladder sphincter function (daily self-assessment and ultrasonic
measurement of the residual and urgency urinary volume),
spasticity scale (SPAST-88, Appendix S4), SF-36 quality of life
scale (Appendix S5), HTLV-1 proviral load in venous blood and in
CSF, total CD4+ lymphocytes, CD8+ lymphocytes and
%CD4+CD25+ T lymphocytes counts and plasma b2 microglobin
as inflammatory markers.
Author Summary
HTLV-1 is a retrovirus transmitted through body fluids that
is commonly seen in the West Indies, South America and
Southern Japan but rarely in the UK. Although most
patients remain healthy carriers, HTLV-1 causes serious
conditions such as adult T cell leukaemia/lymphoma
(ATLL) and HTLV-1-associated myelopathy/Tropical Spastic
Paraparesis (HAM/TSP). The infection which is life-long
cannot be eradicated and treatments for the associated
diseases are limited. We report the encouraging findings of
the first UK Medical Research Council funded treatment
study for patients with early and/or deteriorating HAM/
TSP. Treatment with ciclosporin A, a drug commonly used
to dampen the immune system in transplant patients, was
investigated. Symptoms and signs of disease, particularly
low back pain and muscle stiffness, improved by week 24
and in some patients this improvement persisted after the
48 weeks of treatment, at least to the end of the study at
week 72. Most striking was the finding that the amount of
HTLV-1 in the fluid around the spinal cord, called
cerebrospinal fluid, was reduced during treatment. These
findings justify the further study of ciclosporin A in
patients with HAM/TSP.
Ciclosporin A Treatment for HAM/TSP
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Statistical methods. Data were collected at baseline (2
visits), week 2, week 4 and then four weekly until week 24, 8-
weekly until week 48 and 12-weekly to week 72. Data were
entered into Oracle databases, and checked manually and by
computer consistency checks. Analysis text files were created from
the database and imported into STATA (version 11; Stata
Corporation, College Station, Texas, USA) for statistical analysis.
Week 0 was defined as the date of the second baseline visit; for
numerical variables, the baseline measurement was defined as the
average of the measurements taken at screening (first baseline
visit) and week 0 (second baseline visit). Intention to treat (ITT),
data from all time-points on all patients who commenced CsA
even if they subsequently stopped the drug, and per-protocol (PP)
analysis, data from time-points up to discontinuation of CsA or
re-start of CsA after 48 weeks for secondary outcomes, were
performed. Secondary outcomes were analysed as average
change from baseline to a given time point as measured by area
under the curve minus baseline (AUCMB) using the t-test.
Comparisons were also made between the AUCMB at 24 weeks
with the AUC minus week 24 (AUCM24) at 48 weeks, and the
AUCMB at 48 weeks with the AUC minus week 48 (AUCM48)
at 72 weeks, using paired t-tests. Missing values at baseline, week
24 or week 48, in order to calculate AUCMB, AUBM24 and
AUCM48 were approximated by linear extrapolation to the two
nearest values. As CSF outcomes were only measured at week 12,
changes from baseline for these outcomes were analysed by
regression analysis. Timed walk rank was calculated by ranking
the time to walk 10 meters over all patients and visits, in the
following order (highest/worst score to lowest/best score): unable
to walk; able to walk, but not able to complete 10 meters (ranked
on distance walked and time taken); able to walk 10 meters with a
bilateral aid; able to walk 10 meters with a unilateral aid; able to
walk 10 meters unaided (all ranked on time taken). For example,
there were 99 occasions when timed walk was recorded for all
patients; patient HC036005 was the fastest patient on these 99
occasions to walk 10 m, unaided, taking 7 seconds at each week
2, 4, 8, 12 and 24 visits, so this patient at these visits was given the
lowest score of 1; patient HC036006 did not complete a timed
walk at 0 and 2 week visits since wheelchair bound, so this patient
at these visits was given the highest score of 98; all patients and
visits in-between these extremes were ranked in order as
described above.
Results
Study population, treatment and follow up
We aimed to recruit eight patients. Of the nine eligible patients
with definite, early or progressing HAM/TSP informed of the
study, seven agreed to participate (Figure 1). Baseline demo-
graphic, clinical and laboratory characteristics of the patients are
shown in Table 1. Patients were on average 50 years old (range
40–69), mostly female (5 of 7) and of Afro-Caribbean origin
having acquired HTLV-1 either through mother-to-child trans-
mission or sexual intercourse. As per protocol one patient with
early disease (0.8 years) was entered into the study without a three
months follow up period. The remainder had progressing disease
with documented deterioration in timed walk .50% over the
previous three months. All seven patients initiated treatment with
body weight adjusted CsA (2.5 mg/kg/day) with a median daily
dose of 180 mg (range 160–240). The median trough CsA
concentration from the 59 measurements was 87 mg/ml (range
46–164) with 44% of all measurements within the target range
(Figure 2). Patients were followed up for a median of 74 weeks
(range 71–92).
Primary outcomes
Five patients (72%) completed the 48 weeks of treatment
without interruption. Two of these patients requested to re-start
CsA during the 24 week post therapy follow-up period due to
clinical deterioration which they attributed to stopping CsA.
Over 6.4 person-years follow-up to 48 weeks, no patient failed
according to the first primary outcome criterion i.e. objective
improvement was observed in all patients.
However four patients met the 2nd and 3rd criteria for clinical
failure by 48 weeks, which gives an incidence of 0.6 per person-
year, although only two were true clinical failures as detailed
below.
One patient failed on the second criterion with a .2 point
deterioration of IPEC1 scale on two consecutive visits during
therapy at visit weeks 8 and 12. This patient, with a history of
urinary tract infections (UTI), developed a further UTI and
became depressed during treatment with CsA, which was
discontinued at week 16. Of the three patients who failed due to
.30% deterioration in TW (3rd criterion), two were technical
failures (at weeks 4 and 33 respectively) with temporary
deteriorations due to accidents rather than progression of
HAM/TSP and both continued CsA. The third patient developed
headache and tremor attributed to CsA which was discontinued at
week four but the deterioration in TW was documented at week
45, off treatment. By intention-to-treat, 2/7 patients clinically
failed this trial, and both had to discontinue CsA due to side-
effects.
Secondary outcomes (Table 2)
Objective clinical measures. Trends in timed walk were
biased by the two patients whose accidents during the study caused
a marked, but reversible, deterioration in timed walk. Therefore
timed walk rank, which takes into account walking aids, was
analysed. This showed a trend towards improvement compared to
baseline at 12 weeks with a mean (SE) decrease in score of 27 (5),
p = 0.24 (ITT, Table 2), which was maintained to week 48 and to
week 72 (after treatment had stopped), by ITT and PP analysis
(Figure 3). Compared to baseline changes in IPEC-1 were small
with or without treatment (Table 2). Spasticity (MASS) improved
at all time points compared to baseline, with a decrease in score of
20.3 or 20.4, although changes did not reach statistical
significance (Figure 4, Table 2). Ultrasonic measurements of
residual and urge volume were difficult to interpret because two
patients had urinary catheters.
Subjective clinical measures. The average maximum pain
score (VAS) improved over time: (mean (SE) decrease compared to
baseline at week 24 was ITT: 1.2 cm (0.5), p = 0.05; PP: 1.2 cm
(0.5), p = 0.05) which was maintained to some degree post-
treatment (Figure 5, Table 2). IPEC2 showed a trend towards
improvement throughout follow up compared to baseline which
was greatest in the first 24 weeks (mean (SE) decrease at week 24
and week 48 was ITT: 22.5 (2.2), p = 0.31 and 21.2 (1.8),
p = 0.54 respectively; PP: 22.7 (2.0), p = 0.25 and 21.2 (1.8),
p = 0.54 respectively; AUCM24 to 48 weeks p = 0.08 (ITT), 0.03
(PP)); the improvement continued to 72 weeks (Table 2). Urinary
frequency improved with treatment (a mean decrease of approx-
imately once a day/night), with nocturia improving slightly more
than daytime frequency, although only daytime frequency changes
reached statistical significance as there was more variation in
nocturia frequencies, and this improvement was maintained to
some degree post-treatment (Table 2). The number of episodes of
incontinence did not change significantly either way during trial.
Self-reported MSWS-12, SF-36 and SPAST-88 fluctuated over
time but not markedly.
Ciclosporin A Treatment for HAM/TSP
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Laboratory measures. A small, mean (SE) 0.12 (0.06) log10,
but consistent reduction in HTLV-1 proviral load in peripheral
blood, measured as HTLV-1 DNA copies per 100 PBMCs, was
observed during treatment, which persisted post-treatment
(Figure 6, Table 2, Table 3). A mean (SE) 0.4 (0.15) log10
reduction in HTLV-1 proviral load in CSF at 12 weeks compared
with baseline CSF examination was observed (p = 0.05, Table 2,
4). The ratio of CSF/blood viral load decreased more than four-
fold during the first 12 weeks of CsA treatment (p = 0.14, Figure 7,
Table 2) where as CSF WCC and protein increased by (mean (SE)
7.2 106/L (3.0), p = 0.06, and 0.13 g/L (0.10), p = 0.24, compared
to baseline, respectively).
The absolute counts of lymphocytes, CD4+ T-lymphocytes and
CD8+ T lymphocytes gradually and consistently decreased during
treatment with CsA particularly the CD4+ lymphocytes which
were almost 300 cells/mL fewer on average at week 48 compared
with baseline (p = 0.02, Table 2). These cell counts were still lower
than baseline at week 72, i.e. 24 weeks after treatment cessation.
The proportion of CD4+ lymphocytes expressing CD25+ also
decreased, particularly during the first 12 weeks of therapy (mean
(SE) decrease of 23.3% (2.6), p = 0.25, compared to baseline),
remained lower than baseline through to 48 weeks and had
returned towards baseline 24 weeks after CsA was stopped
(Table 2). Changes were particularly marked in those patients who
had an elevated frequency at baseline (Figure 8).
Plasma b2 microglobulin, decreased with treatment and stayed
at the 48 week level (mean (SE) decrease of 20.31 mg/L (0.39),
p = 0.45, compared to baseline), without further treatment, at 72
weeks (Table 2). These changes were particularly marked in those
patients who had elevated b2 microglobulin levels at baseline
(Figure 9).
Safety and tolerance
All patients remained normotensive with no evidence of
nephrotoxicity.
Grade 1/2 serious adverse events were documented in four
patients: one patient developed community acquired pneumonia
at week 2, which was thought not to be due to CsA treatment,
Figure 1. Flowchart of enrolment and follow up of patients with definite and early and/or progressing HAM/TSP. 50 patients with
HAM/TSP were identified and 9 were identified as patients with early and/or deteriorating HAM/TSP, 7 of whom consented to treatment with
ciclosporin A. Two patients chose to re-start ciclosporin A after 48 weeks during trial period.
doi:10.1371/journal.pntd.0001675.g001
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Table 1. Demographics, and baseline clinical and laboratory measures of patients with HAM/TSP receiving ciclosporin A (n = 7);
median (ranges) or number (%) given.
Age (years) 50 (40–69)
Female 5 (71%)
Likely mode of infection:
Mother to child 3 (43%)
Sexual intercourse 1 (14%)
Mother to child or sexual intercourse 3 (43%)
Ethnic origin:
Afro-Caribbean 5 (71%)
White 2 (28%)
Body weight (kg) 79 (64–100)
Duration of HAM/TSP (years) 4.6 (0.8–17.3)
Clinical measures – objective
Time to walk (seconds/10 meter) 29.5 (8.0–68.0)
1 patient unaided 8
2 patients unilateral walking aid 27.3 (25.0–29.5)
4 patients bilateral walking aid 50.3 (27.0–68.0)
IPEC 1 Disability Scale Score (min 0- max 29) 14.5 (2.5–18.5)
Modified Ashworth Scale Score (min 0- max 4) 1.8 (0.0–2.5)
Bladder Residual volumea (ml) 8 (0–267)
Bladder Urge volumea (ml) 237 (190–417)
Clinical measures – subjective
Maximum pain (min 0- max 10) 8.4 (0.0–9.5)
IPEC 2 Disability Scale Score (min 0- max 43.25) 32.7 (15.5–40.5)
Daily urinary frequencya (per day) 5 (4–7)
Nocturia frequencya (per night) 3 (1–5)
Number of episodes of incontinencea (per 24 hours) 0.0 (0–0.2)
Total MSWS-12 (transformedb) 93 (19–96)
Average MSWS-12 (min 1- max 5) 4.7 (1.8–4.8)
Total Spasticity Scale-88 score (transformedb) 591 (113–736)
Total SF-36 Score (transformedb) 218 (100–610)
Laboratory measures
HTLV-1 proviral DNA (blood) (copies/100 PBMCs) 14.4 (4.8–32.0)
Log10 HTLV-1 proviral DNA (blood) (copies/100 PBMCs) 1.2 (0.7–1.5)
Protein (CSF) (g/L) 0.46 (0.34–0.62)
WCC (CSF) (106/L)c 3.5 (1–8)
Log10 HTLV-1 proviral DNA (CSF) (copies/100 nucleated cells) 1.7 (1.5–2.6)
CSF/PBMC ratio 4.4 (1.0–17.1)
CD4 absolute cell count (106/L) 1595 (805–2260)
CD4% 53 (47–62)
CD8 absolute cell count (106/L) 690 (230–1195)
CD8% 29 (15–35)
CD25% 43 (37–62)
CD4/CD25% 14 (7–30)
CD4/CD25 absolute (106/L) 203 (94–526)
Total lymphocytes (106/L) 3000 (1350–3500)
Absolute HTLV-1 proviral burden (total lymphocytes 106/L6copies/100PBMCs) 26369 (6461–111983)
b-2 microgobulin (mg/L) 2.6 (1.6–6.1)
a: N = 5, 2 patients had catheters;
b: (observed score-min possible score)/(max possible score-min possible score)6100;
c: N = 6. Abbreviations: IPEC disability scale = Insituto de Pesquisa Clinica Evandro Chagas; MSWS=multiple sclerosis walking scale; WCC=white cell count;
CSF = cerebrospinal fluid; PBMC=peripheral blood mononuclear cells.
doi:10.1371/journal.pntd.0001675.t001
Ciclosporin A Treatment for HAM/TSP
www.plosntds.org 5 June 2012 | Volume 6 | Issue 6 | e1675
since she was known to have bronchiectasis and did not develop
any further infections during 48 weeks of CsA treatment. One
patient developed an acute urinary tract infection as well as acute
depression during week 7. Both were not thought to be CsA
related by the Data and Safety Monitoring Committee (DMSC),
but the patient herself opted against CsA, which was stopped.
Tremor and headache, which were reported by the third patient
at week 6, are well described side effects and their pathogenesis
with CsA is not well understood. Tremor was the only side-effect
that was thought to be truly due to CsA in this patient and it
resolved with treatment cessation. The patient’s headaches were
adjudged to be possibly due to long term fungal sinus infection
which was retrospectively reported on a pre-trial head CT scan.
The headaches did not resolve when CsA was stopped.
Concomitant medication taken during the trial
Although many concomitant medications were taken by the
study participants both for symptomatic management of HAM/
TSP and for co-existent pathologies, changes to treatments that
could have influenced clinical outcomes, e.g. muscle relaxants for
spasticity or sympathomimetics for urgency, were avoided during
the study.
Discussion
A recently published review of all therapy studies in patients
with HAM/TSP found that only 86 patients with HAM/TSP
have to date taken therapy within randomised controlled trials
[11]. Two of these studies, enrolling a total of 40 patients, have
found the approach of attempting to reduce HTLV-1 proviral
burden by inhibiting HTLV-1 reverse transcriptase to improve
symptoms, to be disappointing [23,24]. Other open label, proof of
concept studies with immune-modulators such as humanised anti-
Tac (daclizumab) and interferon-b1 have reported a decrease in
peripheral HTLV-1 DNA or tax RNA proviral load as well as
some improvement of motor function with dacluzimab [25,26].
Open, observational studies describe short term improvement in
motor function of HAM/TSP patients with corticosteroids or
interferon-a (IFNb) [12,13]. An open, randomised trial compared
the efficacy of three dosages of IFNa and demonstrated transient,
beneficial effects most marked with the highest dose [14].
The aim of the current study was to identify a safe, long-term,
oral, corticosteroid sparing, anti-inflammatory and immunosup-
pressive treatment option for patients with HAM/TSP.
CsA, was selected to determine whether the course of a disease
which is believed to be caused by heightened immune activation
against chronic HTLV-1 infection could be modified by modulating
T-cell activation, thereby giving further insight into pathogenesis.
The chief characteristic that distinguishes this trial from all
other clinical trials in HAM/TSP are the very strict eligibility
criteria, allowing recruitment of only those patients with early or
progressing disease. It was considered that these patients would be
most likely to benefit from medical intervention and that this
would reduce the likelihood of under-estimating the potential of
therapy. Although the comparison of the investigational drug with
a placebo or another treatment option was not considered
appropriate in the absence of any safety or efficacy data in
patients with HAM/TSP, a comparison of on treatment data with
each patient’s his/her own repeat baseline measures are useful to
identify a treatment signal in a small group of patients.
None of the patients were lost to follow up and all were followed
up at the set time points prospectively aiming to capture pre, on and
post treatment data. CsA’s effect on disease was described by area
under the curve analyses, a useful tool in summarising changes over
Figure 2. Therapeutic drug monitoring of ciclosporin A: dosing and through CsA plasma concentrations.
doi:10.1371/journal.pntd.0001675.g002
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Table 2. Secondary outcomes measured in patients with HAM/TSP receiving Ciclosporin A.
Intention to treat analysis (N=7) Area under the curve minus… mean (SE) p-value p-value
Time to walk rank baseline to 12 weeks 27 (5) 0.24 -
baseline to 24 weeks 28 (4) 0.14 -
baseline to 48 weeks 28 (5) 0.14 -
24 weeks to 48 weeks 3 (2) 0.28 0.07a
48 weeks to 72 weeks 1 (2) 0.75 0.22b
Modified Ashworth Scale Score baseline to 12 weeks 20.3 (0.2) 0.2 -
baseline to 24 weeks 20.3 (0.3) 0.23 -
baseline to 48 weeks 20.4 (0.3) 0.29 -
24 weeks to 48 weeks 0.0 (0.2) 0.86 0.31a
48 weeks to 72 weeks 0.1 (0.2) 0.54 0.32b
Maximum pain baseline to 12 weeks 20.9 (0.4) 0.04 -
(visual analogue scale) baseline to 24 weeks 21.2 (0.5) 0.05 -
baseline to 48 weeks 21.6 (0.8) 0.09 -
24 weeks to 48 weeks 20.1 (0.5) 0.78 0.13a
48 weeks to 72 weeks 0.8 (0.7) 0.27 0.09b
IPEC 1 Disability Scale Score baseline to 12 weeks 20.04 (0.90) 0.97
baseline to 24 weeks 0.03 (0.85) 0.97
baseline to 48 weeks 0.03 (0.79) 0.98
24 weeks to 48 weeks 20.05 (0.31) 0.87 0.92a
48 weeks to 72 weeks 0.78 (0.38) 0.08 0.30b
IPEC 2 Disability Scale Score baseline to 12 weeks 22.0 (2.1) 0.38
baseline to 24 weeks 22.5 (2.2) 0.31
baseline to 48 weeks 21.2 (1.8) 0.54
24 weeks to 48 weeks 4.1 (1.8) 0.06 0.08a
48 weeks to 72 weeks 0.1 (0.8) 0.88 0.43b
Daily urinary frequencyc baseline to 12 weeks 20.8 (0.2) 0.02
baseline to 24 weeks 20.9 (0.2) 0.01
baseline to 48 weeks 20.9 (0.2) 0.01
24 weeks to 48 weeks 20.1 (0.2) 0.7 0.08a
48 weeks to 72 weeks 20.3 (0.1) 0.08 0.08b
Nocturia frequencyc baseline to 12 weeks 21.0 (0.5) 0.13
baseline to 24 weeks 21.2 (0.5) 0.08
baseline to 48 weeks 21.3 (0.6) 0.1
24 weeks to 48 weeks 20.2 (0.2) 0.47 0.07a
48 weeks to 72 weeks 0.5 (0.3) 0.11 0.06b
log10 HTLV-1 DNA (blood) baseline to 12 weeks 20.12 (0.07) 0.16 -
(copies/100 PBMCs) baseline to 24 weeks 20.11 (0.08) 0.2 -
baseline to 48 weeks 20.12 (0.06) 0.08 -
24 weeks to 48 weeks 20.04 (0.07) 0.61 0.63a
48 weeks to 72 weeks 0.05 (0.06) 0.4 0.12b
Protein (CSF) (g/L) change from baseline to 12 wksd 0.13 (0.10) 0.24 -
WCC (CSF) (106/L)e change from baseline to 12 wksd 7.2 (3.0) 0.06 -
log10 HTLV-1 DNA (CSF) baseline to 12 weeks 20.19 (0.08) 0.05 -
change from baseline to 12 wksd 20.39 (0.15) 0.05
CSF/PBMC ratio baseline to 12 weeks 22.2 (1.3) 0.14 -
change from baseline to 12 wksd 24.4 (2.6) 0.14
CD4 absolute cell count (106/L) baseline to 12 weeks 2125 (84) 0.19 -
baseline to 24 weeks 2231 (89) 0.04 -
baseline to 48 weeks 2286 (94) 0.02 -
24 weeks to 48 weeks 42 (28) 0.18 0.05a
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Table 2. Cont.
Intention to treat analysis (N=7) Area under the curve minus… mean (SE) p-value p-value
48 weeks to 72 weeks 64 (55) 0.29 0.03b
CD8 absolute cell count (106/L) baseline to 12 weeks 260 (65) 0.39 -
baseline to 24 weeks 2115 (70) 0.15 -
baseline to 48 weeks 2127 (74) 0.14 -
24 weeks to 48 weeks 62 (28) 0.06 0.08a
48 weeks to 72 weeks 17 (39) 0.68 0.21b
CD4/CD25% baseline to 12 weeks 23.3 (2.6) 23.9 (2.7) 0.25 -
baseline to 24 weeks 24.4 (2.4) 0.2 -
baseline to 48 weeks 20.6 (1.3) 0.11 -
24 weeks to 48 weeks 1.4 (1.5) 0.67 0.25a
48 weeks to 72 weeks 0.39 0.07b
b2microglobin (mg/L) baseline to 12 weeks 20.09 (0.33) 0.77 -
baseline to 24 weeks 20.12 (0.39) 0.78 -
baseline to 48 weeks 20.31 (0.39) 0.45 -
24 weeks to 48 weeks 20.11 (0.14) 0.46 0.99a
48 weeks to 72 weeks 0.03 (0.11) 0.77 0.50b
a: for difference between AUC minus baseline to 24 weeks and AUC minus 24 weeks at 48 weeks;
b: for difference between AUC minus baseline to 48 weeks and AUC minus 48 weeks at 72 weeks;
c: N = 5, 2 patients had catheters;
d: regression analysis;
e: N = 6. IPEC disability scale = Insituto de Pesquisa Clinica Evandro Chagas; WCC =white cell count; CSF = cerebrospinal fluid; PBMC=peripheral blood mononuclear
cells.
doi:10.1371/journal.pntd.0001675.t002
Figure 3. Timed walk ranked by walking aid used (0–72 weeks). A higher rank represents a slower walk. HC036005 walked unaided;
HC036001, HC036004 one walking stick; HC036002, HC036003, HC036006, HC036007 needed 2 walking sticks. At week 0 and 2 HC036006 needed a
wheelchair due to a sprained ankle.
doi:10.1371/journal.pntd.0001675.g003
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Figure 4. Modified Ashworth Scale testing muscle spasticity (0–72 weeks). A higher score represents increased muscle tone.
doi:10.1371/journal.pntd.0001675.g004
Figure 5. Maximum pain over time (0–72 weeks). A higher score represents more pain. If pain was reported at more than one site, the higher
pain score was used.
doi:10.1371/journal.pntd.0001675.g005
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time in a small number of patients whose measurements tend to
fluctuate. However, due to the small sample size and number of
outcomes analysed, the statistical results presented should be
interpreted with caution.
The sample size is small for two reasons, one because of the
stringent recruitment criteria, recruiting only ‘‘early and/or pro-
gressing’’ HAM/TSP and two to make sure this treatment, whilst
known to be fairly safe and well tolerated given for other conditions,
would also be safe in HTLV-1 infected patients who have a 4–6%
background risk of developing ATLL.
This study focused on capturing specifically improvement in
mobility as well as safety with CsA since these are the two most
important outcomes to patients.
Reassuringly CsA was well tolerated by 5/7 patients for 48
weeks, did not have any severe adverse outcomes at 48 or 72 weeks
and most importantly no patient has been diagnosed with any
malignant disease or opportunistic infection during routine follow
up to July 2011 (up to 5 years additional follow up).
We measured the time a patient takes to walk 10 meters, taking
into account aid usage, as well as IPEC 1 disability scale as
outcome measures apart from objective overall improvement.
10 m timed walk increased the sensitivity of measuring change in
mobility, while IPEC 1, which like Osame’s Motor Disability Scale
(OMDS) was developed specifically for patients with HAM/TSP,
included many other clinical symptoms of HAM/TSP, although
it’s assessment of gait is crude. In this study patients, whose
mobility was deteriorating at baseline, showed an overall clinical
improvement after initiating treatment with CsA within a short
period of time (6 months). CsA treatment was associated with
specific improvements in timed walk corrected for aid usage, pain,
Figure 6. Log10 HTLV-1 proviral DNA in peripheral blood mononuclear cells (PBMCs) (0–72 weeks).
doi:10.1371/journal.pntd.0001675.g006
Table 3. Log10 HTLV-1 proviral DNA (blood) (copies/100 PBMCs): 0–48 weeks whilst on CsA treatment; 49–72 weeks without
treatment.
Time since entry (weeks)
22 0 2 4 8 12 16 20 24 32 40 48 60 72
HC036001 0.74 0.70 0.58 0.39 0.67 1.09 0.48 0.63 0.64 0.30 0.62 0.38 0.22 0.61
HC036002 0.87 0.94 0.91 1.25 0.96 1.09 0.92 1.18 0.96 0.68 0.88 0.67 0.36 1.34
HC036003 0.68 0.53 0.49 0.76 0.80 0.75 1.01 0.97 0.56 0.57 0.64 0.70 1.05
HC036004 1.59 1.11 0.79 1.12 0.80 1.40 1.27 0.87 1.05 0.95 1.10 1.16 1.27 1.06
HC036005 1.38 1.29 1.29 1.67 1.36 1.09 1.30 1.31 1.18 1.55 1.28 1.45 1.50 1.73
HC036006 1.33 1.63 0.96 1.26 0.99 1.16 0.98 0.95 1.02 1.39 1.32 0.96 1.61 0.97
HC036007 1.12 1.19 1.19 0.82 0.92 0.58 0.97 1.29 0.88 1.32 1.24 0.96 0.92 1.01
doi:10.1371/journal.pntd.0001675.t003
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spasticity, daily urinary frequency and nocturia. This degree of
improvement was unexpected, since five patients had been
symptomatic for a long time (.2.5 to 17 years) including, as
illustrated in Figure 10, patients with marked thoracic cord
atrophy. Interestingly, despite the TDM driven dose adjustments
CsA trough concentrations were below the target minimum on
33.9% of occasions, therefore the potential efficacy of CsA may
have been underestimated in this study. Two patients opted to
restart treatment during the follow up phase, due to worsening of
symptoms after 48 weeks of treatment.
Although CsA treatment seemed to yield most clinical benefits
by 24 weeks the laboratory markers continued to improve up to 48
weeks. In the subset of patients with high baseline concentrations
plasma b2 microglobulin normalised. b2 microglobulin, which has
recently been demonstrated to distinguish patients with HAM/
TSP from HTLV-1 asymptomatic carriers with a relationship
between concentration and degree of motor disability [27] should
therefore be tested in larger clinical trials as a peripheral blood
surrogate marker of HAM/TSP response to therapy. The
observed reductions in b2 microglobulin and CD4
+ CD25+ T cell
frequency are encouraging both in their own right and particularly
in association with the clinical findings. Furthermore the
unexpected, albeit small reduction in HTLV-1 proviral load,
which appears to be independent of the change in CD4+CD25+
frequency (data not shown) suggests that clinical benefits of
immunosuppressive therapy were not at the expense of reduced
HTLV-1 specific immunity. In theory a reduction HTLV-1
infected CD4+ CD25+ cells would be associated with a reduction
in total HTLV-1DNA load but the reduction in CD4+ cells
expressing CD25+ may also occur in HTLV-1 uninfected cells as a
direct consequence of CsA therapy or even secondary to a reduced
host response to secondary to a reduction in the number of cells
capable of expressing viral proteins.
High HTLV-1 proviral load in CSF, compared with PBMCs, is
recognised as a marker of HAM/TSP [28,29]. The four-fold
greater reduction in HTLV-1 proviral load in the CSF compared
with PBMCs, therefore seems biologically significant, the more so
for being independent of other, traditional markers of CSF
inflammation such as lymphocyte counts and protein. One
possibility is that with T-cell activation inhibition, fewer infected
CD4+ T cells were migrating across the blood-brain barrier. This
observation needs to be further tested in future studies including
later sampling post therapy to determine the duration/reversibility
of this change.
The optimal duration of therapy remains unknown. Whilst
some participants maintained an improved clinical status after
discontinuing therapy after 48 weeks others appeared to relapse
Table 4. Log10 HTLV-1 proviral DNA (CSF): 22 is baseline
evaluation and week 12 CSF was collected while on CsA
treatment.
Time since entry (weeks)
22 12
HC036001 1.70 1.66
HC036002 1.51 0.87
HC036003 1.91 1.02
HC036004 1.62 1.34
HC036005 2.57 1.70
HC036006 1.63 1.60
HC036007 1.70 1.76
doi:10.1371/journal.pntd.0001675.t004
Figure 7. HTLV-1 proviral DNA of cerebro-spinal fluid over peripheral blood mononuclear cells (CSF/PBMC ratio) (0–12 weeks).
doi:10.1371/journal.pntd.0001675.g007
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early. Future, larger, clinical trials of CsA, should therefore
consider treating patients for at least 48 weeks. One study
participant recently relapsed again after stopping CsA for the
second time, after 4 years of therapy.
In conclusion CsA, a steroid-sparing immunosuppressive agent,
was associated with improved disease outcome in patients with
early or progressing HAM/TSP at 24 and 48 weeks follow up.
This finding suggests that activated lymphocytes contribute to
Figure 8. T cell activation marker: absolute CD4+/CD25+ T cell count (0–72 weeks).
doi:10.1371/journal.pntd.0001675.g008
Figure 9. b2 microglobulin a marker of inflammation in peripheral venous blood (0–72 weeks).
doi:10.1371/journal.pntd.0001675.g009
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pathogenesis. This study also demonstrates that close monitoring,
even of patients with long standing HAM/TSP, is important to
detect those with clinically progressive disease who may benefit
from disease modifying therapy.
A multi-centre, international randomised controlled trial in
patients with early and/or progressive HAM/TSP is the next step
towards the establishment of an internationally acknowledged
treatment protocol. Therefore the currently most commonly
prescribed drug for active HAM/TSP, corticosteroids, as well as
steroid sparing drugs such as INF-a, INF-b and CsA should be
studied in larger phase 2 studies either in placebo-controlled or
head-to-head comparative randomised controlled trials.
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